BCM
CPRX icon

BlueCrest Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History

BlueCrest Capital Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-119,054
Closed -$516K – 807
2015
Q1 		$516K Buy
+119,054
New +$429K 0.03% 455

Other funds holding CPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CCA
Catalyst Capital Advisors Huntington, New York $5.37B AUM 18.53% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BlueCrest Capital Management's CPRX Position: Q2 2015 in Review

BlueCrest Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2015, closing a stake of 119,054 shares — an estimated $516K sold.

BlueCrest Capital Management first reported a position in CPRX in Q1 2015 and held it in 1 quarter. The position peaked at $516K in Q1 2015. 87 funds tracked by Wall St. Rank hold CPRX as of Q2 2015.

  • BlueCrest Capital Management reported no remaining Catalyst Pharmaceutical position as of Q2 2015 after selling out during the quarter.
  • BlueCrest Capital Management sold 119,054 Catalyst Pharmaceutical shares in Q2 2015, an estimated $516K.
  • BlueCrest Capital Management first reported a position in Catalyst Pharmaceutical in Q1 2015 and held it in 1 quarter.
  • BlueCrest Capital Management's Catalyst Pharmaceutical position peaked at $516K in Q1 2015.
  • 87 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2015.

Based on BlueCrest Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.